The role of presepsin in the diagnosis and assessment of severity of sepsis and severe pneumonia

The aim of this study was to evaluate marker of inflammation presepsin to improve diagnosis of severe pneumonia, sepsis. Materials and methods. 75 patients with pneumonia, sepsis, other inflammatory diseases aged from 17 to 78 years were examined. These patients have been investigated for the level of the presepsin. Presepsin level was quantified on immunohemilyuministsentny analyzer Pathfast (Mitsubishi Chemical Medience Corporation, Japan) in pg/ml. All patients had obtained an antibacterial therapy in other health care organizations before entering the hospital. Results. Presepsin at the general group of patients with pneumogenic sepsis was 3196.9 +/- 1202.16 pg/mL (n=14, (x) over bar +/- m), with abdominal sepsis - 2506.7 +/- 448.32 pg/mL (n=28), with other inflammatory diseases - 671.6 +/- 124.55 pg/mL (n=11). Presepsin of patients with pneumogenic sepsis was 1125.3 +/- 240.59 pg/mL (n=3), presepsin of patients with severe pneumonia was - 362.6 +/- 76.29 pg/mL (n=13, p<0.05), non-severe pneumonia - 157.3 +/- 33.02 pg/mL (n=9, p<0.05). Conclusion. The high level of presepsin is an indication of an active infectious disease and reflects the severity of the pneumonia and development of sepsis. Keeping a high level against the backdrop of earlier presepsin ongoing antibiotic therapy is an indication of their lack of effectiveness. A significant variability of presepsin should be taken into account.